Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling

Abstract

The p53 tumor suppressor is activated in response to various stresses driving the cells into growth arrest or apoptosis. We have addressed the question of how disintegration of microtubule system induces activation of p53. Depolymerization of microtubules by colcemid in rat and human quiescent fibroblasts resulted in accumulation of transcriptionally active p53 that caused cell-cycle arrest at the G1/S boundary. The p53 activation correlated with prominent activation of Erk1/2 MAP kinases that resulted from colcemid-stimulated development of focal adhesions. Inhibition of focal contacts development by plating of cells onto poly-L-lysine abrogated both Erk1/2 and p53 activations in colcemid-treated cells, while plating of cells onto fibronectin caused transient up-regulation of p53 even in the absence of colcemid. Pre-treatment of cells with the specific MEK1 inhibitor PD098059 also attenuated colcemid-induced p53 activation and G1 cell cycle arrest. Cell types which either failed to develop focal adhesions in response to colcemid treatment (human MCF-7 epithelial cells), or lacked colcemid-induced sustained Erk activation (primary mouse embryo fibroblasts and 12(1) cells) showed virtually no p53 up-regulation in response to disruption of microtubules during G0/G1. Our results indicate that p53 activation is not triggered by disintegration of microtubule system by itself, but rather originates from some of the consequences of such disintegration, in particular, from the development of focal adhesions leading to activation of Erk signaling pathway.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Agapova LS, Ivanov AV, Sablina AA, Kopnin PB, Sokova OI, Chumakov PM and Kopnin BP. . 1999 Oncogene 18: 3135–3142.

  • Amundson SA, Myers TG and Fornace AJJ. . 1998 Oncogene 17: 3287–3299.

  • Ashcroft M and Vousden KH. . 1999 Oncogene 18: 7637–7643.

  • Bachelder RE, Marchetti A, Falcioni R, Soddu S and Mercurio AM. . 1999 J. Biol. Chem. 274: 20733–20737.

  • Bershadsky A, Chausovsky A, Becker E, Lyubimova A and Geiger B. . 1996 Current Biol. 6: 1279–1289.

  • Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J and Neckers L. . 1995 Cancer Res. 55: 4623–4626.

  • Buckbinder L, Talbott R, Seizinger BR and Kley N. . 1994 Proc. Natl Acad. Sci. USA 91: 10640–10644.

  • Chehab NH, Malikzay A, Appel M and Halazonetis TD. . 2000 Genes Dev. 14: 278–288.

  • el-Deiry WS. . 1998 Sem. Cancer Biol. 8: 345–357.

  • Enomoto T. . 1996 Cell Struct. Funct. 21: 317–326.

  • Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C and Lowe SW. . 2000 Genes Dev. 14: 2015–2027.

  • Giaccia AJ and Kastan MB. . 1998 Genes Dev. 12: 2973–2983.

  • Gopalkrishnan RV, Lam EWF and Kedinger C. . 1998 J. Biol. Chem. 273: 10972–10978.

  • Gottlieb TM and Oren M. . 1996 Bioch. Et Bioph. Acta 1287: 77–102.

  • Harris CC. . 1996 Environm. Health Perspect. 104: 435–439.

  • Harvey DM and Levine AJ. . 1991 Genes Dev. 5: 2375–2385.

  • Howe AK and Juliano RL. . 1998 J. Biol. Chem. 273: 27268–27274.

  • Ishizaka Y, Chernov MV, Burns CM and Stark GR. . 1995 Proc. Natl. Acad. Sci. USA 92: 3224–3228.

  • Jimenez GS, Khan SH, Stommel JM and Wahl GM. . 1999 Oncogene 18: 7656–7665.

  • Kaverina I, Rottner K and Small JV. . 1998 J. Cell Biol. 142: 181–190.

  • Khan SH and Wahl GM. . 1998 Cancer Res. 58: 396–401.

  • Ko LJ and Prives C. . 1996 Genes Dev. 10: 1054–1072.

  • Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR and Gudkov AV. . 1997 EMBO J. 16: 1391–1400.

  • Lakin ND and Jackson S. . 1999 Oncogene 18: 7644–7655.

  • Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R and Brady JN. . 1998 J. Biol Chem. 273: 33048–33053.

  • Lanni JS and Jacks T. . 1998 Mol. Cell. Biol. 18: 1055–1064.

  • Levine AJ. . 1997 Cell 88: 323–331.

  • Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M and Lowe SW. . 1998 Genes Dev. 12: 3008–3019.

  • Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC. . 1994 Oncogene 9: 1799–1805.

  • Miyashita T and Reed JC. . 1995 Cell 80: 293–299.

  • Nie Y, Li HH, Bula CM and Liu X. . 2000 Mol. Cell Biol. 20: 741–748.

  • Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, Kondratov R, Stark GR, Chumakov PM and Gudkov AV. . 1996 Proc. Natl. Acad. Sci. USA 93: 10309–10314.

  • Passalaris TM, Benanti JA, Gewin L, Kiyono T and Galloway DA. . 1999 Mol. Cell. Biol. 19: 5872–5881.

  • Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP and Pelicci PG. . 2000 Nature 406: 207–210.

  • Pletjushkina OJ, Belkin AM, Ivanova OJ, Oliver T, Vasiliev JM and Jacobson K. . 1998 Cell Adh. Comm. 5: 121–135.

  • Prives C. . 1998 Cell 95: 5–8.

  • Prives C and Hall PA. . 1999 J. Pathol. 187: 112–126.

  • Rittling SR and Denhardt DT. . 1992 Oncogene 7: 935–942.

  • Rubtsova SN, Kondratov RV, Kopnin PB, Chumakov PM, Kopnin BP and Vasiliev JM. . 1998 FEBS Lett. 430: 353–357.

  • Sablina AA, Agapova LS, Chumakov PM and Kopnin BP. . 1999 Cell Biol. Intematl. 23: 323–334.

  • Sablina AA, Ilyinskaya GV, Rubtsova SN, Agapova LS, Chumakov PM and Kopnin BP. . 1998 J. Cell Sci. 111: 977–984.

  • Schlaepfer DD, Jones KC and Hunter T. . 1998 Mol. Cell. Biol. 18: 2571–2585.

  • She QB, Chen N and Dong Z. . 2000 J. Biol Chem. 275: 20444–20449.

  • Sherr CJ. . 1998 Genes Dev. 12: 2984–2991.

  • Shieh S, Ahn J, Tamai K, Taya Y and Prives C. . 2000 Genes Dev. 14: 289–300.

  • Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, Oren M and Haupt Y. . 1999 J. Biol Chem. 274: 8371–8374.

  • Sionov RV and Haupt Y. . 1999 Oncogene 18: 6145–6157.

  • Wang LG, Liu XM, Kreis W and Budman DR. . 1999 Cancer Chemother. Pharmacol. 44: 355–361.

  • Waterman MJ, Stavridi ES, Waterman JL and Halazonetis TD. . 1998 Nat. Genet. 19: 175–178.

Download references

Acknowledgements

This work was supported by International Research Scholars Program of the Howard Hughes Medical Institute and the Russian Fund for Basic Research.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sablina, A., Chumakov, P., Levine, A. et al. p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene 20, 899–909 (2001). https://doi.org/10.1038/sj.onc.1204156

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204156

Keywords

This article is cited by

Search

Quick links